The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Intervacc and Dechra extend distribution agreement for Intervacc’s equine strangles vaccine Strangvac by two years
Intervacc AB (publ) announces today that the five-year distribution agreement signed in April 2021 with its partner Dechra Pharmaceuticals PLC has been extended by two years. The extension will take effect in April 2026. The agreement covers Strangvac®, Intervacc’s...Intervacc appoints Anna-Carin Lagerlöf as Sales and Marketing Director
The animal health group Intervacc AB (publ) has appointed Anna-Carin Lagerlöf to the newly established role as Sales and Marketing Director. In this position, Anna-Carin will lead the company’s continued sales growth, with a particular focus on Strangvac® –...Interim report January – June 2025
The Group in summary 01/04/25 01/04/24 01/01/25 01/01/24 Full year -30/06/25 -30/06/24 -30/06/25 -30/06/24 2024 Net sales 7 012 2 735 11 586 5 129 11 787 Operating result...Intervacc’s distribution partner Dechra launches Strangvac in Spain, Portugal and Slovenia
Intervacc AB (publ) announces today that its European distribution partner, Dechra Pharmaceuticals PLC (“Dechra”), is launching Strangvac® in Spain, Portugal and Slovenia. Vials of the vaccine against the highly contagious bacterial equine disease strangles are...Nyhetstjänster
